Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background Recently, a new staging of patients with asymptomatic moderate to severe aortic stenosis (AS) based on extra-aortic valve cardiac damage has been described to stratify the prognostic of both, asymptomatic and symptomatic patients. Purpose To test the ability of this imaging based staging system to predict the development of symptoms in patients with moderate to severe asymptomatic AS. Methods We analyzed a retrospective cohort of 96 patients with at least moderate AS who were systematically studied with echocardiography and cardiac magnetic resonance imaging. Patients were classified according to the staging classification of extra-aortic valve damage: no cardiac damage (Stage 0), left ventricular (LV) damage: LV mass index >95 g/m2 in women and >115 g/m2 in men and or E/E ́ratio >14 and/or LV ejection fraction <50% (Stage 1), mitral valve or left atrial (LA) damage: LA volume >34 ml/m2, and/or atrial fibrillation and/or ≥ moderate mitral regurgitation (Stage 2), tricuspid valve or pulmonary vasculature damage: systolic pulmonary arterial pressure ≥60 mm Hg and/or moderate or greater tricuspid regurgitation (Stage 3), right ventricular damage: tricuspid annulus systolic velocity S ́< 9.5 cm/s, TAPSE < 17 mm, and/or RV ejection fraction < 50% (Stage 4). Given the small number of patients in Stages 3 and 4, patients were merged together in a single group. The primary endpoint was the development of symptoms during a follow-up of 5 years, regardless of whether the patient underwent aortic valve replacement. Kaplan-Meier curves and log-rank test of the time to development of symptoms data were used. Results At baseline patients had a mean age of 70.9 years old and 71.9% were male. Most of patients had hypertension (70.8%) and dyslipidemia (55.2%). 20.8% had diabetes mellitus and only 10.4% had previous coronary artery disease. The mean transvalvular gradient was 39 ± 14 mmHg and the mean aortic valve area was 1.04 ± 0.24 cm2. According to the staging scheme, 37 patients were classified in Stage 0 (38.5%), 32 in Stage 1 (33.3%), 23 in Stage 2 (24%) and 4 in the group of Stage 3-4 (4.2%). During 5 years of follow-up, 44 patients developed symptoms (33 dyspnea, 18 angina and 5 syncope), up to 40% of patients underwent aortic valve replacement and 20 patients died (20.8%), 7 of them due to cardiovascular causes. According to the staging scheme, the proportion of patients who remained asymptomatic at 5 years were: 50.3% in Stage 0, 45.8% in Stage 1, 27.3% in Stage 2, 0% in Stage 3-4 (p = 0.002). Every patient in stages 3 and 4 had developed symptoms by the third year while most patients in stage 0 remained asymptomatic within the first two years (figure 1). Conclusions Up to 45% of asymptomatic patients with moderate to severe AS will develop symptoms within a 5-year period. Symptoms are developed significantly earlier with incremental staging. This classification may be useful to identify patients that deserve a closer follow-up. Abstract Figure. Baseline Characteristics Abstract Figure. Symptoms development

Asymptomatic Aortic Stenosis: From Risk Stratification to Treatment

Natural history of initially asymptomatic severe aortic stenosis: a one-stage meta-analysis

Recent Updates on Asymptomatic and Symptomatic Aortic Valve Stenosis its Diagnosis, Pathogenesis, Management and Future perspectives

Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial

Aortic Outcome after Implementation of a Treatment Strategy for Type B Aortic Dissection Involving the Aortic Arch

Moderate aortic stenosis: Navigating the uncharted

Diagnosis and management of aortic valve stenosis in patients with heart failure

Aortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis: The AVATAR Trial

Incidence and Prognostic Significance of Silent Coronary Disease in Asymptomatic Patients with Severe Aortic Stenosis

Timing of Surgery for Asymptomatic Patients with Severe Aortic Valve Stenosis: an Updated Systematic Review and Meta-Analysis

Optimal treatment of asymptomatic patients with severe aortic stenosis: protocol of a prospective, multicentre, registry study

Moderate Aortic Stenosis-Advanced Imaging, Risk Assessment, and Treatment Strategies

Structural heart disease review of TAVR in low-risk patients: importance of lifetime management

Current Management and Therapy of Severe Aortic Stenosis and Future Perspective

Lifetime Management for Aortic Stenosis: Strategy and Decision Making in the Current Era

Symptoms development overtime according to the imaging based cardiac damage staging classification in asymptomatic patients with moderate to severe aortic stenosis

Severe aortic stenosis: secular trends of incidence and outcomes

From the Pathophysiology to the Intervention, Current Challenges, and Future Perspectives

Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?

Alternative access in transcatheter aortic valve replacement-an updated focused review

ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis